Sally Baron‐Hay

3.3k total citations
48 papers, 775 citations indexed

About

Sally Baron‐Hay is a scholar working on Oncology, Obstetrics and Gynecology and Cancer Research. According to data from OpenAlex, Sally Baron‐Hay has authored 48 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 12 papers in Obstetrics and Gynecology and 11 papers in Cancer Research. Recurrent topics in Sally Baron‐Hay's work include Endometrial and Cervical Cancer Treatments (12 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (7 papers). Sally Baron‐Hay is often cited by papers focused on Endometrial and Cervical Cancer Treatments (12 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (7 papers). Sally Baron‐Hay collaborates with scholars based in Australia, United States and United Kingdom. Sally Baron‐Hay's co-authors include Frances Boyle, Carolyn D. Scott, Michael Friedländer, Susanna B. Park, Matthew C. Kiernan, David Goldstein, Andreas du Bois, Jonathan A. Ledermann, Michael Quinn and Michelle Harrison and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Sally Baron‐Hay

43 papers receiving 758 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sally Baron‐Hay Australia	14	388	237	220	148	122	48	775
Mark K. Dodson United States	15	180 0.5×	209 0.9×	281 1.3×	309 2.1×	87 0.7×	42	870
Yalan Bi China	16	221 0.6×	163 0.7×	134 0.6×	148 1.0×	85 0.7×	51	718
M. A. Bookman United States	9	237 0.6×	102 0.4×	316 1.4×	111 0.8×	95 0.8×	15	583
Loredana Miglietta Italy	17	296 0.8×	145 0.6×	115 0.5×	69 0.5×	54 0.4×	48	605
Glauce Aparecida Pinto Brazil	12	313 0.8×	132 0.6×	74 0.3×	48 0.3×	44 0.4×	40	635
Christine Gennigens Belgium	13	171 0.4×	146 0.6×	95 0.4×	153 1.0×	68 0.6×	55	530
Jørn Andersen Denmark	20	461 1.2×	165 0.7×	425 1.9×	209 1.4×	139 1.1×	36	1.0k
So Fan Yim Hong Kong	13	292 0.8×	287 1.2×	82 0.4×	111 0.8×	259 2.1×	26	909
Tomoyuki Sasano Japan	21	558 1.4×	249 1.1×	184 0.8×	268 1.8×	51 0.4×	44	1.1k
J Chauvergne France	16	353 0.9×	121 0.5×	132 0.6×	166 1.1×	228 1.9×	107	833

Countries citing papers authored by Sally Baron‐Hay

Since Specialization

Citations

This map shows the geographic impact of Sally Baron‐Hay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Baron‐Hay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Baron‐Hay more than expected).

Fields of papers citing papers by Sally Baron‐Hay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally Baron‐Hay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Baron‐Hay. The network helps show where Sally Baron‐Hay may publish in the future.

Co-authorship network of co-authors of Sally Baron‐Hay

This figure shows the co-authorship network connecting the top 25 collaborators of Sally Baron‐Hay. A scholar is included among the top collaborators of Sally Baron‐Hay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Baron‐Hay. Sally Baron‐Hay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zdenkowski, Nicholas, Marion Kuper‐Hommel, Samuel M. Niman, et al.. (2025). Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial. The Lancet Oncology. 26(3). 367–377. 3 indexed citations

Lin, Ning, Eva Ciruelos, G. Jerusalem, et al.. (2024). LBA18 Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results. Annals of Oncology. 35. S1211–S1212. 1 indexed citations

Lok, Sheau Wen, A. Antón, Sally Baron‐Hay, et al.. (2023). Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry.. Journal of Clinical Oncology. 41(16_suppl). e13054–e13054. 1 indexed citations

Friedländer, Michael, Linda Mileshkin, Janine Lombard, et al.. (2023). Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. British Journal of Cancer. 129(5). 797–810. 9 indexed citations

Au‐Yeung, George, Mathias Bressel, Owen W.J. Prall, et al.. (2023). PO003/#269 Ignite: a phase II signal-seeking trial of adavosertib targeting recurrent high grade serous ovarian cancer with cyclin E1 over-expression with and without gene amplification. A2–A3. 2 indexed citations

Lorusso, Domenica, Nicoletta Colombo, Antonio Casado, et al.. (2023). Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice. European Journal of Cancer. 186. 172–184. 6 indexed citations

Lorusso, Domenica, Vicky Makker, Antonio Casado, et al.. (2022). 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. International Journal of Gynecological Cancer. 32. A102–A102. 1 indexed citations

Smith, Deborah S., Kristy Robledo, Sonia Yip, et al.. (2022). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers. 15(1). 254–254. 1 indexed citations

Wong, Vanessa, Richard de Boer, Sally Baron‐Hay, et al.. (2022). Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 22(8). 792–800. 7 indexed citations

10.

Lamoury, Gillian, Susan Carroll, Marita Morgia, et al.. (2022). Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: A systematic review with network meta-analysis. Critical Reviews in Oncology/Hematology. 181. 103898–103898. 6 indexed citations

11.

Antill, Yoland, Peey‐Sei Kok, Kristy Robledo, et al.. (2021). Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. Journal for ImmunoTherapy of Cancer. 9(6). e002255–e002255. 80 indexed citations

12.

Holen, Ingunn, et al.. (2021). Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience. Journal of bone oncology. 31. 100402–100402. 6 indexed citations

13.

Fuchs, Talia L., A. Scott Pearson, Connie I. Diakos, et al.. (2020). Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. Pathology. 52(5). 515–521. 3 indexed citations

14.

Muscat, Andrea, David M. Ashley, Violet Mukaro, et al.. (2019). Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response. PLoS ONE. 14(2). e0210891–e0210891. 14 indexed citations

15.

Baron‐Hay, Sally, Matti Aapro, A. Bernareggi, & Lee S. Schwartzberg. (2019). Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). Supportive Care in Cancer. 27(4). 1309–1317. 5 indexed citations

16.

Antill, Yoland, Peey‐Sei Kok, Martin R. Stockler, et al.. (2019). Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). Annals of Oncology. 30. ix192–ix192. 20 indexed citations

17.

Kandula, Tejaswi, Michelle A. Farrar, Matthew C. Kiernan, et al.. (2017). Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology. 128(7). 1166–1175. 52 indexed citations

18.

McCrary, J. Matt, David Goldstein, Frances Boyle, et al.. (2017). Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer. 25(11). 3485–3493. 67 indexed citations

19.

Heinzelmann‐Schwarz, Viola, Margaret Gardiner‐Garden, Susan M. Henshall, et al.. (2006). A distinct molecular profile associated with mucinous epithelial ovarian cancer. British Journal of Cancer. 94(6). 904–913. 86 indexed citations

20.

Baron‐Hay, Sally, Anthony Clifford, Michael Jackson, & Sharon E. Clarke. (1999). Life threatening laryngeal toxicity following treatment with combined chemoradiotherapy for nasopharyngeal cancer: A case report with review of the literature. Annals of Oncology. 10(9). 1109–1112. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact